GeneQuine Biotherapeutics GmbH
Société
Onglets principaux
À propos de votre organisation / profil
GeneQuine develops next generation gene therapy for musculoskeletal diseases with a potentially disease-modifying lead candidate for osteoarthritis.
In 2017, GeneQuine sold its (then-) lead program for osteoarthritis to Flexion Therapeutics Inc. for up to $64 million.
GeneQuine is currently raising a series A of €16 million to take its second gene therapy drug candidate for osteoarthritis to the clinic, to start a development program for degenerative disc disease, and to expand its lab.
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.
Cette organisation ne comporte pas d'utilisateur pour le moment.
